Treatment of Dyslipidemia in Type 2 Diabetes

Chun YIN,Yihong SUN
DOI: https://doi.org/10.16806/j.cnki.issn.1004-3934.2017.05.002
2017-01-01
Abstract:The main characteristics of dyslipidemia in type 2 diabetes(T2DM) are mild or moderate elevation of low-density lipopro-tein cholesterol,high triglyceride and low high-density lipoprotein cholesterol,with the presence of small and dense low-density lipoprotein particle,and dysfunction of lipoprotein particles. The atherosclerogenic dyslipidemia plays an important role in the development and progress of cardiovascular diseases (CVD) in T2DM and increases the residual risk of CVD. Statins has been proven to be cornerstone treatment in the prevention of CVD in diabetic patients. The benefit of fibrate and niacin on top of statin has been challenging. The emerging new non-sta-tin drugs,such as cholesterol absorption inhibitors and PCSK9 inhibitors could further reduce the residual risk of cardiovascular disease. How-ever,there was increasing concern of the impact lipid lowering therapy on the glucose metabolism.
What problem does this paper attempt to address?